Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 8/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 8/20 | 0.44 |
| ▸ | EPHB4 | P54760 | 6/20 | 0.44 |
| ▸ | EHMT2 | Q96KQ7 | 3/20 | 0.41 |
| ▸ | EHMT1 | Q9H9B1 | 3/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.41 |
| ▸ | FLT1 | P17948 | 2/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 2/20 | 0.39 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29354598 | 1.00 | EPHA2 (0.47) | EPHA2NPC1RAB9AKDREPHB4 | |
| SCHEMBL1098795 | 0.84 | ENPP1 (0.58) | EPHA2NPC1RAB9AKDREPHB4 | |
| SCHEMBL22445632 | 0.80 | EHMT2 (0.52) | EPHA2NPC1RAB9AEHMT2EHMT1 | |
| SCHEMBL5177457 | 0.78 | KDM4E (0.54) | EPHA2NPC1RAB9AKDREPHB4 | |
| SCHEMBL22441517 | 0.77 | EHMT2 (0.49) | EPHA2NPC1RAB9AEHMT2EHMT1 | |
| SCHEMBL22445494 | 0.77 | EHMT2 (0.49) | EPHA2NPC1RAB9AEHMT2EHMT1 | |
| SCHEMBL29357291 | 0.77 | EHMT2 (0.49) | EPHA2NPC1RAB9AEHMT2EHMT1 | |
| SCHEMBL22441436 | 0.77 | KDR (0.60) | KDREHMT2EHMT1FGFR1FLT1 | |
| SCHEMBL29354537 | 0.77 | KDR (0.60) | KDREHMT2EHMT1FGFR1FLT1 | |
| SCHEMBL5201839 | 0.77 | KDR (0.60) | KDREHMT2EHMT1FGFR1FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3941459-B1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-11407729-B2 | Quinoline and quinazoline compounds and methods of use thereof | Stingray Therapeutics, Inc. (US) | 2022-08-09 | — | — | US | disclosed |
| US-11407729-B2 | Quinoline and quinazoline compounds and methods of use thereof | Stingray Therapeutics, Inc. (US) | 2022-08-09 | — | — | US | disclosed |
| EP-3941459-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | Stingray Therapeutics, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| CN-113924092-A | Quinoline and quinazoline compounds and methods of use thereof | 斯汀格瑞治疗股份有限公司 | 2022-01-11 | — | — | CN | disclosed |
| US-20200299258-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2020-09-24 | — | — | US | disclosed |
| US-20200299258-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2020-09-24 | — | — | US | disclosed |
| WO-2020190912-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | Stingray Therapeutics, Inc. (US) | 2020-09-24 | — | — | WO | disclosed |
| WO-2020190912-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | Stingray Therapeutics, Inc. (US) | 2020-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299258-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ENPP1, ENPP3, PDE7A | EPHA2 3365/4885NPC1 1948/4885RAB9A 611/4885 |
| US-11407729-B2 | Quinoline and quinazoline compounds and methods of use thereof | ENPP1, ENPP3, PDE7A | EPHA2 3365/4885NPC1 1948/4885RAB9A 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.